Expert Delphi survey on research and development into drugs for neglected diseases

Fehr A, Thuermann P, Razum O (2011)
BMC Health Services Research 11(1).

Journal Article | Published | English

No fulltext has been uploaded

Author
; ;
Abstract
Background: Tropical infectious diseases are called neglected, because they are, inter alia, characterized by an R&D deficit. A similar deficit exists for rare (orphan) diseases which neither promise a sufficient return on R&D investment. To encourage the development of treatments for rare diseases, orphan drug acts were created which contain financial and non-financial incentives for the pharmaceutical industry. Similar instruments aimed exclusively at neglected diseases do not yet exist. Proposals for a regulatory approach to promote R&D for neglected diseases include the application of selected orphan drug incentives, or the implementation of a Medical Research and Development Treaty (MRDT) with national funding obligations for medical R&D. We compiled and analyzed experts' opinions on causes for the treatment deficit for neglected diseases and on desirable and feasible measures to promote neglected disease R&D. Hereby, the focus was on mechanisms contained in orphan drug regulations and in the Medical Research and Development Treaty draft (Discussion draft 4, 2005). Lastly, we solicited experts' opinions on the desirability and feasibility of a regulatory instrument to foster R&D for neglected diseases. Methods: An international online-Delphi survey was conducted with 117 (first round) and 56 (second round) experts of different professional backgrounds and professional affiliations who formulated and ranked causes and solutions related to the treatment deficit for neglected diseases. Results: In both rounds of survey, the majority of the participating experts (88.4% first round, 86.8% second round) advocated the development of a regulatory instrument to promote R&D for neglected diseases. Most experts (77.9% first round, 79.3% second round) also considered this to be a feasible option. With the exception of market exclusivity, which was viewed critically, key provisions contained in orphan drug regulations were judged favorably also for neglected diseases. A majority (87.1% first round, 77.2% second round) supported national funding obligations for neglected diseases which are proposed by the Medical Research and Development Treaty draft. Conclusions: While not all features of orphan drug regulations and of the MRDT draft received equal support, the view was expressed that a regulatory instrument would be a desirable and feasible measure to promote R&D for neglected diseases.
Publishing Year
ISSN
PUB-ID

Cite this

Fehr A, Thuermann P, Razum O. Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research. 2011;11(1).
Fehr, A., Thuermann, P., & Razum, O. (2011). Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research, 11(1).
Fehr, A., Thuermann, P., and Razum, O. (2011). Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research 11.
Fehr, A., Thuermann, P., & Razum, O., 2011. Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research, 11(1).
A. Fehr, P. Thuermann, and O. Razum, “Expert Delphi survey on research and development into drugs for neglected diseases”, BMC Health Services Research, vol. 11, 2011.
Fehr, A., Thuermann, P., Razum, O.: Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Services Research. 11, (2011).
Fehr, Angela, Thuermann, Petra, and Razum, Oliver. “Expert Delphi survey on research and development into drugs for neglected diseases”. BMC Health Services Research 11.1 (2011).
This data publication is cited in the following publications:
This publication cites the following data publications:

45 References

Data provided by Europe PubMed Central.

Public health, innovation and intellectual property rights
AUTHOR UNKNOWN, 2006
Medical Research and Development Treaty (MRDT)
AUTHOR UNKNOWN, 2005
Research and Development. Coordination and Financing
AUTHOR UNKNOWN, 2010
The Policy Delphi
AUTHOR UNKNOWN, 2002
Globalpark Enterprise Feedback Suite 5.2
AUTHOR UNKNOWN, 2007
Zielgeführte Evaluation von Programmen - ein Leitfaden
AUTHOR UNKNOWN, 2000

AUTHOR UNKNOWN, 2002
Government-Controlled Pharmaceutical Research and Development: A Recipe for Desaster
AUTHOR UNKNOWN, 2006
Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act
AUTHOR UNKNOWN, 2005
Editorial: drug development for neglected diseases: a public health challenge.
Fehr A, Thurmann P, Razum O., Trop. Med. Int. Health 11(9), 2006
PMID: 16930253
Macroeconomics and Health: Investing in Health for Economic Development
AUTHOR UNKNOWN, 2001
Global strategy and plan of action on public health, innovation and intellectual property
AUTHOR UNKNOWN, 2008
Proposal by Bangladesh, Barbados, Bolivia and Suriname
AUTHOR UNKNOWN, 2009
Patens and R&D Incentives: comments on the Hubbard and Love Trade Framework for Financing Pharmaceutical R&D
AUTHOR UNKNOWN, 2004
A Global Medical Research and Development Treaty. An answer to global health needs?
AUTHOR UNKNOWN, 2007
A new trade framework for global healthcare R&D.
Hubbard T, Love J., PLoS Biol. 2(2), 2004
PMID: 14966544
Reply to the comments requested by CIPIH and WHO to the CPTech proposal for a Medical Research and Development Treaty (MRDT)
AUTHOR UNKNOWN, 2005
Review of CPTech Proposal for an R&D Treaty
AUTHOR UNKNOWN, 2005
Expanding global research and development for neglected diseases.
Winters DJ., Bull. World Health Organ. 84(5), 2006
PMID: 16710555

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 22087801
PubMed | Europe PMC

Search this title in

Google Scholar